Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

被引：115
|
作者：
Barnett, Richard [1 ]
Barta, Valerie S. [1 ]
Jhaveri, Kenar D. [1 ]
机构：
[1] Hofstra Northwell Sch Med, Hempstead, NY 11549 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 02期
关键词：
IPILIMUMAB; MELANOMA;
D O I：
10.1056/NEJMc1614298
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：191 / 192
页数：2
相关论文
共 50 条
  • [21] Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding
    Shin, Jong
    Phelan, Paul J.
    Gjoerup, Ole
    Bachovchin, William
    Bullock, Peter A.
    PROTEIN EXPRESSION AND PURIFICATION, 2021, 177
  • [22] Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
    Amini-Adle, M.
    Khanafer, N.
    Le-Bouar, M.
    Duru, G.
    Dalle, S.
    Thomas, L.
    BMC CANCER, 2018, 18
  • [23] A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma
    Shalhout, Sophia Z.
    Emerick, Kevin S.
    Kaufman, Howard L.
    Silk, Ann W.
    Thakuria, Manisha
    Miller, David M.
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (07) : 299 - 302
  • [24] PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward
    Pal, Sumanta K.
    Singh, Parminder
    Vogelzang, Nicholas J.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 257 - 260
  • [25] PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'
    Gonzalez, Raul S.
    Salaria, Safia N.
    Bohannon, Caitlin D.
    Huber, Aaron R.
    Feely, Michael M.
    Shi, Chanjuan
    HISTOPATHOLOGY, 2017, 70 (04) : 558 - 567
  • [26] Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
    Glutsch, Valerie
    Graen, Franziska
    Weber, Judith
    Gesierich, Anja
    Goebeler, Matthias
    Schilling, Bastian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [27] Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
    Escandon, Julia
    Peacock, Stephanie
    Trabolsi, Asaad
    Thomas, David B.
    Layka, Ayman
    Lutzky, Jose
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [28] Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
    Wagner, Lars M.
    Adams, Val R.
    ONCOTARGETS AND THERAPY, 2017, 10 : 2097 - 2106
  • [29] Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma
    Santos-Briz, Angel
    Canueto, Javier
    Del Carmen, Sofia
    Barrios, Beatriz
    Yuste, Manuela
    Bellido, Lorena
    Dolores Ludena, Maria
    Roman, Concepcion
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2021, 43 (06) : 423 - 428
  • [30] PD-1/PD-L1 Inhibitor- Related Adverse Events and Their Management in Breast Cancer
    Lei, Chuqi
    Kong, Xiangyi
    Li, Yuan
    Yang, Huaiyu
    Zhang, Ke
    Wang, Zhongzhao
    Chang, Hu
    Xuan, Lixue
    JOURNAL OF CANCER, 2024, 15 (09): : 2770 - 2787
12345